Community Acquired Pneumonia: Outcome, Quality of Life and Immune Status

Completed

Conditions: host defense
Immune response
10021460
10004018

Registration Number: NL-OMON40285

Lead Sponsor: Sint Antonius Ziekenhuis

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Completed

Sex: Not specified

Target Recruitment: 140

Inclusion Criteria

1. Patients who participated in the Ovidius or Triple-P study (2004-2009).
2. Diagnosis in these studies with pneumococcal pneumonia or pneumonia due another identified organism.
3. Age * 18 years.
4. Signing of informed consent.

Exclusion Criteria

1. Diagnosis of pneumonia without an identified causative organism.
2. Fever at time of vaccination.
3. Previous/known allergic reaction to any of the components of the vaccine given.
4. Mentally incompetent.
5. Previous pneumococcal vaccination.
6. Clinical pneumonia within 1 month prior to inclusion.

Study & Design

Study Type: Observational invasive

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Immune response to pneumococcal vaccination in patients who were diagnosed with<br /><br>CAP due to S. pneumoniae in comparison with patients with another causative<br /><br>pathogen. Main parameters are antibody titres against the different<br /><br>pneumococcal serotypes before and after vaccination and avidity maturation of<br /><br>these antibodies. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>* To investigate antibody response after pneumococcal vaccination in patients<br /><br>with community acquired pneumococcal pneumonia in the past who failed to elicit<br /><br>a specific antibody response previously.<br /><br>* To investigate the cellular immune responses after pneumococcal vaccination<br /><br>in patients with community acquired pneumococcal pneumonia in the past compared<br /><br>to pneumonia patients with another pathogen..<br /><br>* To investigate quality of life by the RAND-36 score in patients with a<br /><br>community acquired pneumonia in the past.<br /><br>* To investigate the long-term mortality after community acquired pneumococcal<br /><br>pneumonia.</p><br>